ALT — Altimmune Inc

Stock analysis, trade plans, and proprietary indicators by Trend Edge.

About Altimmune Inc

Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. Read full Trend Edge analysis →

Trend Edge Proprietary Indicators

Key Metrics

Current Price$2.90
Market Cap$572M
Float164.2M
Shares Outstanding194.5M
P/E (Forward)8.18
Price/Sales (TTM)15,882.06
vs. Analyst Target+453.6% to analyst PT
Operating Margin (TTM)-267247.22%
Revenue (TTM)$36,000
Dividend RateNone
Analyst Target Price$16.06 (9 analysts)

Financial History

Annual Revenue & Earnings History

YearRevenueNet IncomeGross ProfitEBITDA
2020 $8.2M -$49.0M -$25.3M -$38.1M
2021 $4.4M -$97.1M $4.4M -$96.5M
2022 -$68,000 -$84.7M -$68,000 -$84.4M
2023 $426,000 -$88.4M $426,000 -$87.9M
2024 $20,000 -$95.1M $20,000 -$94.8M
2025 $41,000 -$88.1M $41,000 -$87.0M

Recent Quarterly Revenue & Net Income

QuarterRevenueNet Income
Jun 2025 $5,000 -$22.1M
Sep 2025 $5,000 -$19.0M
Dec 2025 $26,000 -$27.4M
Mar 2026 N/A -$22.6M

Ownership & Float

Insider Ownership0.4%
Institutional Ownership55.2%
Short Float21.6%
% of All Funds Holding1.87%
Number of Funds Holding154

Current Moving Averages

Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.

TimeframeSMAValueTrend Context
Weekly10-Week SMA$3.09Near-term / short-term trend
Weekly40-Week SMA$3.95Medium-term trend
Weekly80-Week SMA$4.97Cyclical trend (business cycle)
Weekly200-Week SMA$6.83Secular trend (multi-year)
Monthly10-Month SMA$3.90Near-term monthly trend
Monthly20-Month SMA$4.90Medium-term monthly trend
Monthly40-Month SMA$5.61Secular monthly trend

Volume Shelves — Support & Resistance

Trend Edge identifies volume shelves: price zones where historically elevated trading volume creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.

Price LevelTypeVolume RatioAge
$3.10 resistance 1.22x 0 months ago
$6.70 resistance 1.05x 13 months ago

Historical Earnings Reactions (36 events)

TimeframeAvg ReturnMedianWin RateBestWorst
Gap 1.33% 0.30% 55.56% 23.49% -6.46%
1 Day 2.26% 0.66% 52.78% 26.07% -8.52%
1 Week -1.50% -2.11% 38.89% 47.22% -24.77%
2 Weeks 2.42% -4.49% 37.14% 124.70% -27.93%
1 Month 3.13% -1.14% 45.71% 94.39% -66.48%

Next earnings: August 1, 2026 (66 days away)

Seasonality & Day-of-Week Patterns

Monthly Seasonality

MonthAvg ReturnWin RateSamples
Jan7.3%33.3%9
Feb9.8%44.4%9
Mar-21.9%11.1%9
Apr-10.4%33.3%9
May21.4%50.0%8
Jun2.0%22.2%9
Jul9.1%33.3%9
Aug9.1%44.4%9
Sep-18.4%11.1%9
Oct-2.4%33.3%9
Nov4.0%44.4%9
Dec25.0%44.4%9

Day-of-Week Tendencies

DayAvg ReturnWin RateSamples
Monday -0.31% 42.3% 423
Tuesday 0.22% 45.5% 464
Wednesday 0.57% 43.6% 461
Thursday -0.00% 44.8% 453
Friday 0.18% 45.8% 454

Top Institutional Holders

Institutional holder breakdown coming soon.

Total institutional ownership: 55.2%

Insider Transactions — Smart Summary

Total insider ownership: 0.4%

12-Month Insider Activity Summary

Total Filings10
Net Value+$167,089
Net Shares Change90,227
% of Float0.1%
C-Suite Filings4
Clusters Detected2

Key Insiders

NameTitleNet ValueFilingsActivity
Durso Jerome Benedict President and CEO +$169,458.75 3 3 buy
GILL JOHN +$82,599.92 2 2 buy
WEAVER GREGORY L Chief Financial Officer +$49,199 2 2 buy
Pisano Wayne +$20,410 1 1 buy
Sohn Catherine A. +$2,117.55 1 1 buy
Jorkasky Diane +$2,002.6 1 1 buy

Transaction Clusters

PeriodFilingsInsidersNet ValueSeniority
2025-12-22 – 2026-01-05 4 4 +$106,938.9
2026-04-01 – 2026-04-06 3 3 +$109,948.92 2 C-suite

Significant Filings

DateInsiderTitleNet ValuePrice After
2026-04-01 WEAVER GREGORY L Chief Financial Officer +$31,499 Transaction at $3.15, now -7.9%
2026-04-01 Durso Jerome Benedict President and CEO +$47,100 Transaction at $3.14, now -7.6%
2026-03-09 WEAVER GREGORY L Chief Financial Officer +$17,700 Transaction at $3.54, now -18.1%
2026-03-09 Durso Jerome Benedict President and CEO +$70,790 Transaction at $3.54, now -18.1%
2026-04-06 GILL JOHN +$31,349.92 Transaction at $3.41, now -14.9%
2026-01-09 Pisano Wayne +$20,410 Transaction at $4.08, now -29.0%

View full insider transaction history on Trend Edge →

AI Consult Analysis

Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Altimmune Inc (ALT) powered by Claude Opus — Anthropic's most capable AI model. The analysis covers five layers: technical analysis (near-term, medium-term, cyclical, and secular trend, momentum, volume shelf support and resistance, breakout and breakdown signals), qualitative analysis (business model, competitive moat, sector dynamics), insider sentiment (buy and sell signals from executive and director transactions), share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and fundamental analysis (valuation, revenue growth, profit margin, earnings quality).

AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit, stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward. Whether you are building a long position, initiating a short, or looking for a reversal setup, AI Consult identifies the highest-probability signal from the current trend.

Get the full AI Consult analysis for ALT on Trend Edge →